Halozyme Therapeutics vs US Dollar/Swiss Franc FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Halozyme Therapeutics Inc (HALO)

Q3 202615 Jul – 14 Aug 2026

▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.
This is the biggest new financial event, directly boosting investor confidence and the stock price.
New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.
This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.
Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.
It reinforces demand for an existing partnered product, which drives recurring royalty revenue.
Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.
This captures the market's positive reaction and momentum, which can attract more investors.

July 202615 Jul – 14 Aug 2026

▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.
This is the biggest new financial event, directly boosting investor confidence and the stock price.
New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.
This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.
Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.
It reinforces demand for an existing partnered product, which drives recurring royalty revenue.
Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.
This captures the market's positive reaction and momentum, which can attract more investors.

Latest15 Jul – 14 Aug 2026

▲4

Halozyme's Q2 Beat and New Incyte Deal Drive Growth Story

Q2 earnings beat and raised guidance Halozyme reported Q2 revenue of $481 million, up 48% from a year ago, and raised its full-year revenue outlook to $1.835–$1.910 billion. The stock jumped 20% on the news, as investors saw stronger demand for its drug-delivery technology and better profit potential.
This is the biggest new financial event, directly boosting investor confidence and the stock price.
New Incyte collaboration for ENHANZE Halozyme signed a global licensing deal with Incyte to use its ENHANZE technology with an experimental cancer drug. Halozyme gets upfront cash, potential milestone payments, and future royalties. This expands its partner base and adds a new stream of income without major new spending.
This is a fresh partnership that adds future revenue and validates Halozyme's technology platform.
Positive trial results for Darzalex Faspro A late-stage trial showed that Darzalex Faspro, which uses Halozyme's ENHANZE technology, combined with J&J's Talvey significantly improved survival in multiple myeloma patients. This supports continued adoption of the drug, meaning more royalties for Halozyme over time.
It reinforces demand for an existing partnered product, which drives recurring royalty revenue.
Stock hits 52-week high on momentum Halozyme shares reached a 52-week high of $103.30 after the strong earnings and guidance. The stock has risen 46% over the past year, reflecting growing investor confidence in its business model and cash generation.
This captures the market's positive reaction and momentum, which can attract more investors.

US Dollar/Swiss Franc FX Spot Rate (USDCHF.FOREX)

Q3 202618 Jun – 15 Jul 2026

▲2▼2

SNB holds at zero, Fed rate bets and safe-haven flows drive USD/CHF

SNB holds rates at zero, ready to weaken franc The Swiss National Bank kept its key rate at zero and said it is increasingly willing to step into currency markets to stop the franc from getting too strong. That caps the franc and supports USD/CHF, because a central bank that fights franc strength makes holding francs less rewarding.
This is the main policy force keeping a floor under USD/CHF.
Fed rate-hike expectations and safe-haven dollar demand Renewed US-Iran tensions and rising oil prices boosted the safe-haven dollar, while Fed minutes showed some officials open to a rate hike and markets priced a 62% chance of a September increase. Higher expected US rates pull money into dollars, lifting USD/CHF.
This explains the dollar side of the pair and the recent push higher.
Weak US jobs and inflation data weigh on the dollar A weak US Nonfarm Payrolls report and slower June Producer Price Index growth, plus dovish comments from Fed officials, pushed the dollar down and USD/CHF to around 0.8034. Softer US data reduce the chance of Fed rate hikes, which weakens the dollar against the franc.
This is the main counterweight pulling USD/CHF lower.
AI-driven hedging flows support the franc Bank of America says currency hedging tied to the AI stock boom is now a bigger FX driver than usual fundamentals, and these flows have generally supported the Swiss franc while putting modest selling pressure on the dollar. That works against USD/CHF.
It is a structural flow that adds to franc strength, a real counterweight.

July 202618 Jun – 15 Jul 2026

▲2▼2

SNB holds at zero, Fed rate bets and safe-haven flows drive USD/CHF

SNB holds rates at zero, ready to weaken franc The Swiss National Bank kept its key rate at zero and said it is increasingly willing to step into currency markets to stop the franc from getting too strong. That caps the franc and supports USD/CHF, because a central bank that fights franc strength makes holding francs less rewarding.
This is the main policy force keeping a floor under USD/CHF.
Fed rate-hike expectations and safe-haven dollar demand Renewed US-Iran tensions and rising oil prices boosted the safe-haven dollar, while Fed minutes showed some officials open to a rate hike and markets priced a 62% chance of a September increase. Higher expected US rates pull money into dollars, lifting USD/CHF.
This explains the dollar side of the pair and the recent push higher.
Weak US jobs and inflation data weigh on the dollar A weak US Nonfarm Payrolls report and slower June Producer Price Index growth, plus dovish comments from Fed officials, pushed the dollar down and USD/CHF to around 0.8034. Softer US data reduce the chance of Fed rate hikes, which weakens the dollar against the franc.
This is the main counterweight pulling USD/CHF lower.
AI-driven hedging flows support the franc Bank of America says currency hedging tied to the AI stock boom is now a bigger FX driver than usual fundamentals, and these flows have generally supported the Swiss franc while putting modest selling pressure on the dollar. That works against USD/CHF.
It is a structural flow that adds to franc strength, a real counterweight.

Latest18 Jun – 15 Jul 2026

▲2▼2

SNB holds at zero, Fed rate bets and safe-haven flows drive USD/CHF

SNB holds rates at zero, ready to weaken franc The Swiss National Bank kept its key rate at zero and said it is increasingly willing to step into currency markets to stop the franc from getting too strong. That caps the franc and supports USD/CHF, because a central bank that fights franc strength makes holding francs less rewarding.
This is the main policy force keeping a floor under USD/CHF.
Fed rate-hike expectations and safe-haven dollar demand Renewed US-Iran tensions and rising oil prices boosted the safe-haven dollar, while Fed minutes showed some officials open to a rate hike and markets priced a 62% chance of a September increase. Higher expected US rates pull money into dollars, lifting USD/CHF.
This explains the dollar side of the pair and the recent push higher.
Weak US jobs and inflation data weigh on the dollar A weak US Nonfarm Payrolls report and slower June Producer Price Index growth, plus dovish comments from Fed officials, pushed the dollar down and USD/CHF to around 0.8034. Softer US data reduce the chance of Fed rate hikes, which weakens the dollar against the franc.
This is the main counterweight pulling USD/CHF lower.
AI-driven hedging flows support the franc Bank of America says currency hedging tied to the AI stock boom is now a bigger FX driver than usual fundamentals, and these flows have generally supported the Swiss franc while putting modest selling pressure on the dollar. That works against USD/CHF.
It is a structural flow that adds to franc strength, a real counterweight.